Table 3 Demography and morbidity of the propensity matched cohort.
Propensity matched cohort | p | |||
|---|---|---|---|---|
Bacteremic n = 172 | Non bacteremic n = 172 | |||
Age, median (IQR) | 67 (59–75) | 66 (55–74) | 0.42 | |
Gender, female (%) | 76 (40) | 84 (44) | 0.41 | |
Charlson CI, median (IQR) | 1 (0–2) | 1 (0–2) | 0.89 | |
Liver disease (%) | 4 (2) | 3 (2) | 0.74 | |
Renal disease (%) | 15 (9) | 9 (5) | 0.20 | |
Diabetes mellitus (%) | 34 (20) | 36 (21) | 0.79 | |
Cardiovascular disease (%) | 41 (24) | 48 (28) | 0.39 | |
Cerebral disease (%) | 17 (10) | 20 (12) | 0.60 | |
COPD (%) | 15 (9) | 22 (13) | 0.22 | |
Connective tissue disease (%) | 13 (8) | 15 (9) | 0.69 | |
Peptic ulcer disease (%) | 10 (6) | 7 (4) | 0.46 | |
Malignancy (%) | 45 (26) | 46 (27) | 0.90 | |
Immunosuppressant (%) | 46 (27) | 40 (23) | 0.46 | |
Preceding antibiotic therapy (%) | 60 (35) | 59 (34) | 0.91 | |
Foci | ||||
Respiratory tract (%) | 39 (23) | 38 (22) | 0.90 | |
Urinary tract (%) | 11 (6) | 11 (6) | 1.0 | |
Abdominal (%) | 38 (22) | 40 (23) | 0.80 | |
Bone & joint (%) | 5 (3) | 4 (2) | 0.74 | |
Skin & soft tissue (%) | 20 (12) | 16 (9) | 0.48 | |
Other (%) | 59 (34) | 63 (37) | 0.65 | |
Outcome | ||||
ICU mortality (%) | 49 (29) | 37 (22) | 0.14 | |
90-day mortality (%) | 81 (47) | 62 (36) | 0.04 | |
Severity of disease | ||||
SOFA max, median (IQR) | 12 (9–16) | 10 (7–13) | < 0.01 | |
SOFA resp max, median (IQR) | 3 (2–4) | 3 (3–4) | 0.33 | |
SOFA renal max, median (IQR) | 2 (0–4) | 1 (0–3) | 0.02 | |
SOFA liver max, median (IQR) | 0 (0–2) | 0 (0–1) | 0.05 | |
SOFA coag max, median (IQR) | 2 (0–3) | 1 (0–2) | < 0.01 | |
SOFA cardiovasc max, median (IQR) | 3 (1–4) | 3 (1–4) | 0.58 | |
SOFA CNS max, median (IQR) | 1 (0–3) | 1 (0–2) | 0.28 | |
Lactate max, mmol/L, median (IQR) | 4.4 (3.0–8.0) | 3.8 (2.4–6.5) | < 0.01 | |
